BR112015002183A2 - processos para a preparação de (s) -3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona e formas farmaceuticamente aceitáveis da mesma - Google Patents

processos para a preparação de (s) -3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona e formas farmaceuticamente aceitáveis da mesma

Info

Publication number
BR112015002183A2
BR112015002183A2 BR112015002183A BR112015002183A BR112015002183A2 BR 112015002183 A2 BR112015002183 A2 BR 112015002183A2 BR 112015002183 A BR112015002183 A BR 112015002183A BR 112015002183 A BR112015002183 A BR 112015002183A BR 112015002183 A2 BR112015002183 A2 BR 112015002183A2
Authority
BR
Brazil
Prior art keywords
morpholinomethyl
dione
piperidine
oxy
benzyl
Prior art date
Application number
BR112015002183A
Other languages
English (en)
Inventor
M Cohen Benjamin
Zhang Chengmin
B Feigelson Gregg
F Traverse John
W Leong William
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR112015002183A2 publication Critical patent/BR112015002183A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo “processos para a preparação de (s) -3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona e formas farmaceuticamente aceitáveis da mesma.” são fornecidos processos para a preparação de 3-(4 -((4-(morfolinometil)benzil)oxi) -1-oxoisoindolino-2-il)piperidina-2,6-diona enantiomericamente enriquecida ou enantiomericamente pura, ou uma forma farmaceuticamente aceitável da mesma. 1 1 / 1
BR112015002183A 2012-08-09 2013-08-08 processos para a preparação de (s) -3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona e formas farmaceuticamente aceitáveis da mesma BR112015002183A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261681477P 2012-08-09 2012-08-09
PCT/US2013/054099 WO2014025978A1 (en) 2012-08-09 2013-08-08 Processes for the preparation of (s)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof

Publications (1)

Publication Number Publication Date
BR112015002183A2 true BR112015002183A2 (pt) 2017-07-04

Family

ID=49035933

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015002183A BR112015002183A2 (pt) 2012-08-09 2013-08-08 processos para a preparação de (s) -3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona e formas farmaceuticamente aceitáveis da mesma

Country Status (19)

Country Link
US (2) US9309220B2 (pt)
EP (2) EP3466942B1 (pt)
JP (1) JP6444866B2 (pt)
KR (1) KR20150041650A (pt)
CN (1) CN104718202B (pt)
AU (1) AU2013299559B2 (pt)
BR (1) BR112015002183A2 (pt)
CA (2) CA2879151C (pt)
CR (1) CR20150051A (pt)
EC (1) ECSP15004585A (pt)
ES (2) ES2914876T3 (pt)
HK (1) HK1211577A1 (pt)
IL (1) IL236925A0 (pt)
IN (1) IN2015DN00845A (pt)
MX (1) MX2015001633A (pt)
PH (1) PH12015500214A1 (pt)
RU (1) RU2015108057A (pt)
SG (1) SG11201500984QA (pt)
WO (1) WO2014025978A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3202461T1 (sl) 2010-02-11 2019-05-31 Celgene Corporation Derivati arilmetoksi izoindolina in sestavki, ki jih vsebujejo in metode uporabe le teh
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
EP2943201B2 (en) 2013-01-14 2020-07-29 Deuterx, LLC 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
WO2014152833A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
MX2020002010A (es) 2017-08-21 2020-07-13 Celgene Corp Procesos para la preparacion de 4,5-diamino-5-oxopentanoato de (s)-terc-butilo.
US11529339B2 (en) 2018-10-01 2022-12-20 Celgene Corporation Combination therapy for the treatment of cancer
CN110194760B (zh) * 2019-05-27 2021-08-17 浙江农林大学暨阳学院 制备3-亚苄基-2-（7’-喹啉）-2,3-二氢-异吲哚-1-酮类化合物的方法
CN113896711A (zh) 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 杂环类免疫调节剂
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
EP2479172B1 (en) * 2004-09-03 2013-10-09 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
ES2430545T3 (es) * 2005-06-30 2013-11-21 Celgene Corporation Procedimientos para la preparación de compuestos de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolina-1,3-diona
KR20090121400A (ko) 2007-03-20 2009-11-25 셀진 코포레이션 4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법
SI3202461T1 (sl) * 2010-02-11 2019-05-31 Celgene Corporation Derivati arilmetoksi izoindolina in sestavki, ki jih vsebujejo in metode uporabe le teh
CA2793312C (en) 2010-03-08 2016-06-14 Natco Pharma Limited Anhydrous lenalidomide form-i
ES2671608T3 (es) 2012-02-21 2018-06-07 Celgene Corporation Formas sólidas de 3-(4-nitro-1-oxoisoindolin-2-il)piperidina-2,6-diona

Also Published As

Publication number Publication date
CA2879151C (en) 2021-03-30
IL236925A0 (en) 2015-03-31
PH12015500214A1 (en) 2015-04-27
IN2015DN00845A (pt) 2015-06-12
AU2013299559A1 (en) 2015-02-05
SG11201500984QA (en) 2015-04-29
US9309220B2 (en) 2016-04-12
WO2014025978A1 (en) 2014-02-13
CA3108974C (en) 2023-04-04
ECSP15004585A (es) 2015-12-31
CA2879151A1 (en) 2014-02-13
US20160251333A1 (en) 2016-09-01
CR20150051A (es) 2015-05-11
AU2013299559B2 (en) 2017-08-17
US20140046058A1 (en) 2014-02-13
EP2882736B1 (en) 2019-01-09
US9975872B2 (en) 2018-05-22
EP3466942B1 (en) 2022-04-20
JP6444866B2 (ja) 2018-12-26
CA3108974A1 (en) 2014-02-13
CN104718202A (zh) 2015-06-17
JP2015524481A (ja) 2015-08-24
ES2914876T3 (es) 2022-06-17
RU2015108057A (ru) 2016-09-27
EP2882736A1 (en) 2015-06-17
ES2712652T3 (es) 2019-05-14
KR20150041650A (ko) 2015-04-16
MX2015001633A (es) 2015-04-08
HK1211577A1 (en) 2016-05-27
CN104718202B (zh) 2018-11-20
EP3466942A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
BR112015002183A2 (pt) processos para a preparação de (s) -3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona e formas farmaceuticamente aceitáveis da mesma
CR20150050A (es) Sales y formas solidas de (s)-3-(4-((4-(morfolinometil) bencil) oxi)-1-oxoisoindolin-2-il) piperidin-2, 6-diona y composiciones que comprenden y métodos para utilizar las mismas
CY1119974T1 (el) Στερεες μορφες 3-(5-αμινο-2-μεθυλ-4-οξο-4η-κιναζολιν-3-υλ)-πιπεριδινο-2,6-διονης και φαρμακευτικες συνθεσεις και χρησεις αυτης
DK2882442T3 (da) Fremgangsmåder til behandling af cancer under anvendelse af 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
IL244494A0 (en) Formulations of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-6,2-dione
WO2014028445A3 (en) Cereblon isoforms and their use as biomarkers for therapeutic treatment
CL2018000811A1 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
MX2018006005A (es) Formulaciones que comprenden sales de oxalato de teneligliptin y solvatos de este.
AR077909A1 (es) Intervenciones de urgencia de carbon vegetal activo con sobredosificacion con etexilato de dabigatran
TR201902863T4 (tr) Eri̇tropoi̇eti̇n ve seftri̇akson i̇çeren farmasöti̇k bi̇r bi̇leşi̇m ve parki̇nson hastaliği demansinin tedavi̇si̇ i̇çi̇n bi̇r i̇lacin üreti̇lmesi̇nde bunun bi̇r kullanimi.
EA201001756A1 (ru) Комбинированный анальгетик на основе парацетамола

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]